2010

December 2010

CSRC Annual Meeting; Pediatric CV Safety Think Tank

12/09/2010: CSRC Annual Meeting

12/10/2010: CSRC Pediatric CV Drug and Devices Safety Think Tank

October 2010

Development of T2DM Drugs & Cardiovascular Safety Assessments

10/5-6/2010: Development of Type 2 Diabetes Mellitus Drugs: State-of-the-Art Cardiovascular Safety Assessments Oct. 5-6, 2010

Call for abstracts deadline: September 8, 2010

September 2010

Development of T2DM Drugs and Cardiac Safety Assessments

9/23-24/2010: CSRC Co-Sponsors DIA Workshop

Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science.

June 2010

TransRAdial Education Training and Therapy Initiative Think Tank Meeting; Review of CSRC Document “Use of Cardiac Troponin in Clinical Drug Development”

6/23/2010: Shifting the Balance of Potency and Bleeding Risk for Anti-Coagulant and Anti-Platelet Agents Through Radial Arteriotomy 

6/28/2010: Review of CSRC Document “Use of Troponin in Clinical Drug Development”

April 2010

DIA/FDA/Heart Rhythm Society’s CV Safety in Drug Development

 4/11-13/2010: Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding

Co-sponsored by the DIA, FDA, and Heart Rhythm Society; 11-13 April 2010, 9:00am to 5:00pm daily, Sheraton National Hotel, Arlington, Virginia

January 2010

Safety Evaluation of Atrial Fibrillation Ablation Using a Collaborative Pan-Stakeholder Critical Path Registry Model: CSRC Thinktank; CBI’s 4th Annual Cardiac Safety Assessment Summit

1/12-13/2010 CBI’s 4th Annual Cardiac Safety Assessment Summit

The Latest Approaches in the Evaluation of Drugs that Affect Heart Rate, Blood Pressure, QT Prolongation and Other CV Safety Related Issues.

Safety Evaluation of Atrial Fibrillation Ablation Using a Collaborative Pan-Stakeholder Critical Path Registry Model: A CSRC ‘Incubator’ Thinktank

An Educational Collaboration between the Cardiac Safety Research Consortium (CSRC), the Duke Clinical Research Institute (DCRI), the American College of Cardiology (ACC), the Heart Rhythm Society (HRS), AdvaMed, and the United States FDA.